News and Treatment Updates

Myelodysplastic syndromes/neoplasms (MDS) are myeloid malignancies with ineffective hematopoiesis, resulting in variable cytopenias and increased risk of progression to acute myeloid leukemia (AML) [1, 2]. Imetelstat, a first-in-class competitive telomerase inhibitor, is an…

Abstract The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current…

Abstract Venetoclax (Ven) in combination with hypomethylating agents (HMA) (azacitidine or decitabine) is the standard of care for elderly or unfit patients with acute myeloid leukemia (AML) and is being explored in high-risk myelodysplastic syndrome (HR-MDS). However, currently…

Abstract Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified…

Abstract Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified…

Key Points A structured, home-based exercise intervention in MPN was feasible, well accepted, and showed initial benefits on disease-related markers. Physical activity is a potentially safe and accessible adjunct to standard treatments in this population, warranting further study…

Background: Aplastic anemia is a rare, life-threatening condition marked by pancytopenia and bone marrow hypocellularity. Despite therapeutic advances, clinical practice remains variable, and uncertainties persist regarding diagnosis and optimal management. To address these gaps…

The clinical impact of immunosuppression termination (IST) after allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains to be fully elucidated. This study was aimed at assessing the impact of IST within 2 years after transplantation on subsequent clinical…

Measurable residual disease (MRD) monitoring has become a critical component in the management of acute myeloid leukemia (AML), to inform prognosis, guide therapy, and serve as a key end point in clinical trials. The 2025 update of the MRD guideline provides a comprehensive and…

Posttransplant maintenance with venetoclax (Venclexta) plus decitabine (Dacogen) and cedazuridine (Inqovi) following a reduced-intensity conditioning (RIC) transplant regimen of venetoclax plus fludarabine and busulfan (FluBu2), along with tacrolimus (Prograf) plus methotrexate…